Aims This study evaluated health status and health‐related quality of life (HRQOL) among
patients with type 2 diabetes mellitus (T2 DM) treated with dapagliflozin, a highly selective …

Patients with type 2 diabetes (T2DM) and inadequate glycaemic control on combination
metformin (MET) and sulphonylurea (SU) were enrolled in a 24‐week, double‐blind …

Aims This study evaluated change in health‐related quality of life (HRQOL) associated with
ongoing weight change among patients with type 2 diabetes mellitus (T2DM) treated with …

Introduction No study has compared the effects of sodium–glucose cotransporter 2 inhibitors
(SGLT2is) and dipeptidyl peptidase 4 inhibitors (DPP4is) on patients' quality-of-life (QOL) …

Aims To demonstrate the relationships between hypoglycaemia, body mass index (BMI) and
quality of life, and to examine the impact of dapagliflozin on patient‐reported treatment …

Background The benefits of sodium glucose cotransporters 2 (SGLT2) inhibitors in patients
with type 2 diabetes mellitus include plasma glucose control, reduction in body weight and …

Introduction: While ample evidence on improved glycemic control, weight reduction, and
lowered blood pressure (BP) with sodium-glucose cotransporter type 2 inhibitors (SGLT2is) …

Introduction The present study aimed to describe characteristics of patients with type 2
diabetes (T2D) in UK primary care initiated on dapagliflozin, post-dapagliflozin changes in …

The effectiveness of dapagliflozin in the management of type-2 diabetes mellitus (T2-DM) is
an essential issue for establishing a basis for prescribing dapagliflozin. This study aimed to …

Aims To investigate changes in glycated hemoglobin (HbA1c), body weight (BW), and
systolic blood pressure (SBP) in type 2 diabetes (T2D) primary care patients initiating …